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Introduction
99mTc-sestamibi is a myocardial perfusion agent that 
initially distributes in the myocardium proportional to 
flow, similar to thallium-2011,2. Once injected, this 
tracer is quickly taken up by the myocardium and is 
sequestrated in the mitochondria of myocytes3,4. 
According to a previous report, this tracer reportedly 
does not demonstrate significant delayed redistribution 
during low flow5; however, after transient ischemia, 
delayed redistribution often occurs1,2. In an intact 
canine model of low-flow ischemia, the early redis-
tribution of 99mTc-sestamibi and thallium-201 are 
comparable and proportional to flow6; other experi-
mental models have shown that the 99mTc-sestamibi 
Scintigraphic parameters with emphasis on 
perfusion appraisal in rest 99mTc-sestamibi 
SPECT in the recovery of myocardial function 
after thrombolytic therapy in patients with ST 
elevation myocardial infarction (STEMI)
H Javadi,1 MA Porpiranfar,2 S Semnani,1 S Jallalat,1 P Yavari,2 
M Mogharrabi,1 A Hooman,3 A Amini,4 M Barekat,4 D Iranpour,4 
M Seyedabadi,4 M Assadi,4 IN Asli3
Abstract
Introduction: This study was performed to determine the clinical application of rest 99mTc-sestamibi in the assessment 
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is retained only in the viable myocardium7-9. Thus, 
99mTc-sestamibi is not a pure perfusion agent, but 
rather appears to be a metabolic marker of myocardial 
viability in the presence of a critical stenosis. Under 
sustained low flow, however, it is unclear whether 
99mTc-sestamibi will demonstrate rest redistribution, 
providing an index of myocardial viability in the pres-
ence of a critical stenosis10,11.
Reverse redistribution is also reported in patients with 
both hypertrophic cardiomyopathy1 and complete left 
bundle branch block (LBBB)13. In myocardial infarction 
(MI), the reverse redistribution of thallium-201 has fre-
quently been observed14. Takeishi et al. reported a reverse 
redistribution of 99mTc-sestamibi after direct percuta-
neous transluminal coronary angioplasty (PTCA) in 
patients with acute myocardial infarction (AMI), and 
they concluded that the reverse redistribution of 99mTc-
sestamibi indicates successful revascularization and 
predicts preserved left ventricular function15. Arii et al. 
reported that the reverse redistribution of 99mTc- 
sestamibi indicates a salvaged myocardium16. The present 
study investigated perfusion assessment (reperfusion 
and reverse reperfusion) in 99mTc-sestamibi SPECT 
and its relation to myocardial wall motion in patients 
with AMI; in addition, the clinical implications of this 
phenomenon were assessed.
Material and Methods
Participants
Fifty-nine patients who were referred to the cardiology 
clinic at our hospital were invited to participate in our 
study. Eight patients did not respond to the invitation, 
and 6 patients were not interested in participating in the 
study. The remaining 45 cases were willing to take part. 
Of these, three patients, subsequently, were found to be 
ineligible; five patients agreed to join in the study, but did 
not attend their appointments for follow-up MPI; 37 
patients fulfilled the eligibility criteria, provided 
informed consent, and participated in the study.
All patients exhibited the onset of symptoms of AMI 
within six hours before hospitalization, and ST-segment 
elevation of 0·1 mV or more in two or more limbs leads, 
or at least 0·2 mV in two or more precordial leads.
Patients with contraindications to streptokinase, car-
diogenic shock, use of glycoprotein IIb/IIIa antagonists 
or oral anticoagulants within the prior days, or a thera-
peutic dose of heparin or low molecular-weight heparin 
within the previous hours, need for anticoagulant ther-
apy, and, also, any other disease that resulted in the 
patient being at increased risk were excluded.
All patients were treated with streptokinase (1.5 mil-
lion units intravenously over 1 h). Patients also received 
enoxaparin or unfractionated heparin (UFH). Enoxaparin 
was administered as an intravenous bolus (40 mg) and 
then subcutaneously every 12 h (1 mg/kg), with a maxi-
mum of 100 mg for the first two subcutaneous injec-
tions. Also, UFH was to be given for a minimum of 
48 hours and adjusted to the activated partial thrombo-
plastin time, according to the American Heart Association/
American College of Cardiology guidelines, including 
the duration of therapy17,18.
All patients had undergone both resting 99mTc- 
sestamibi SPECT and 2-dimensional (2D) echocardiog-
raphy within 1 week after streptokinase administration. 
Furthermore, all patients were recalled after 3–5 months, 
and follow-up resting 99mTc-sestamibi SPECT and 
echocardiography were carried out.
The study complies with the Declaration of Helsinki 
and was approved by the institutional ethics committee 
of Shaheed Beheshti University of Medical Science. All 
patients signed a written informed consent form.
Imaging Protocol
Myocardial perfusion imaging with 99mTc-sestamibi 
was performed in the first week (4±2 days) and 3–5 
months (mean 123±15.24 days) post anti-thrombotic 
therapy. Fifteen minutes before tracer administration, 
each patient drank a glass of milk to accelerate the tracer 
clearance from the hepatobiliary system and, sub-
sequently, received a total dose of 740 MBq of 99mTc-
sestamibi intravenously at rest. Data acquisition for 
SPECT imaging was performed twice for initial imaging 
at 30 min and for delayed imaging at 180 min after 
99mTc-sestamibi injection. A rotating digital gamma 
camera (ADAC–Pegasys, ADAC Laboratories Inc., 
Milpitas, CA, USA) equipped with a low-energy, all-pur-
pose, parallel whole collimator and a 20% window cen-
tered at 140 keV provided energy discrimination. 
Thirty-two images were then obtained over a 180° arc 
from the 45° right anterior oblique position to the 135° 
left posterior oblique with step and shoot acquisition. 
Each arc image was accumulated for 20 seconds. The data 
were stored on a 64*64 matrix. An expert nuclear medi-
cine specialist used the cine display of the rotating planar 
projections to evaluate sub-diaphragmatic activities, 
attenuations, and patient motion in order to optimize the 
quality of the images. Then, reconstruction processing 
was performed with a Butterworth filter using a 35 cycle/
pixel cut-off and order 6. Reconstructed transaxial images 
were re-oriented in the vertical long axis, horizontal long 
axis, and axial short axis of the left vertical axis.
Image Analysis
The left ventricular wall was divided into 20 segments 
and the perfusion uptake percentage and perfusion score 
of each segment, along with the activity of the lung to 
heart ratio (LHR), were acquired. For LV uptake mea-
surement, the segment with maximal tracer uptake among 
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20 segments in the polar map view, congruent to the 
region with the best perfusion, was used as the reference 
region, and Tc-MIBI uptake of each segment was expressed 
as percentage uptake proportional to this reference region.
Image interpretation was supported using standard 
AutoQUANT software (AutoQUANT, Cedars-Sinai, ADAC 
Laboratories). In addition, the left ventricular cavity-to-
myocardium count ratio (CMR) was designed in accord-
ance with procedure proposed by Roberti et al.19 Briefly, a 
rectangular region of interest (ROI) was drawn in the hot-
test area of the left ventricular wall and in the center of the 
left ventricular cavity on the mid-ventricular short-axis 
slice; then, the ratio was calculated (Figure 1). For more 
details, note the previously published manuscript20.
Redistribution was defined when there was a better 
perfusion in the 180 minute view relative to the 30 minute 
view in each set and also reverse redistribution was 
defined as an increase of more than 1 point in the seg-
mental score on the 180 min delayed images.
Two-dimensional echocardiography
The first echocardiograph was carried out at 3±2 days 
and the second at 123±15.24 days. Patients were observed 
at rest in the left lateral decubitus position and a Kontron 
echocardiograph (Kontron, Toulon, France) with a 3.5 
MHz transducer was utilized for the study. Parasternal 
short axis, long axis, apical four chamber, and two cham-
ber views were completed. For left ventricle ejection 
fraction (LVEF) calculation, a monoplane area-length 
method was applied on the four- chamber views. The 
lower limit point of normal LVEF was denoted as 50%21. 
Measurements of chamber dimensions and wall thick-
ness were obtained at the mitral valve-tip level from 
2D-guided M-mode or short-axis-view recordings. The 
predicted normal values for the left ventricular end-
diastolic cavity dimension (LVDD) were calculated from 
Henry’s formula and corrected for age and body surface 
area (BSA)22 as follows: predicted LVDD=45.3 
BSA1/3−0.03(age)−7.2±12%. The percentage predicted 
LVDD (%LVDD) was calculated as (measured LVDD/
predicted LVDD) x 100. The regional wall motion of the 
left ventricle (LV) myocardium was scored visually 
according to: normal=0, mild hypokinesia=1, moderate 
hypokinesia=2, severe hypokinesia=3, akinetic or dyski-
netic=4. Recovery of myocardial function was defined 
as a decreased value in at least one score and/or incre-
mented LVEF ≥5% in the follow-up echocardiogram.
In addition, the left ventricular wall was divided into 
20 segments, similar to myocardial perfusion scan and 
regional wall motion. Each segment was assigned as one of 
five grades by an experienced observer who had no knowl-
edge concerning the scintigraphic findings. The severity 
of the perfusion defect was compared in segments with 
the redistribution and those with a reverse redistribution 
of 99mTc-sestamibi; differences were observed in the 
changes of the wall motion between segments in which the 
reverse redistribution disappeared and those in which it 
remained.
Statistical Analysis
The data were expressed as the mean ±SD; the perfusion 
parameters between dependent groups were studied 
using the paired Student’s t-test. The unpaired Student’s 
t-test was applied for comparison of two groups and 
multiple comparisons were evaluated using analysis of 
variance (ANOVA) with a post-hoc test; differences in 
proportion (categorical variables) were examined by the 
Chi-square test. A two-tailed t-test was used to compare 
the mean values. The relationship between perfusion 
parameters and LVEF was assessed with linear regres-
sion and Pearson’s coefficient. The predictive capacity 
of the perfusion percentage for myocardial function 
recovery was evaluated using cut-off values and receiver 
operating characteristic (ROC) curve analysis; sensitiv-
ity, specificity, and likelihood ratio (LR) were calculated. 
Figure 1. Example of ROIs for CM ratio calculation in a patient 
with a jeopardized myocardium.
Table 1. Patient characteristic
Age 58±14 years
M/F 30/7
Smoking 22 (59.5 %)
IHD 7 (18.9%)
HLP 9(24.3%)
HTN 12(32.4%)
DM 7(18.9%)
Peak of serum CK(IU/L) 1825.32±1981.24 (mean±SD) 
9800-250(range)
Infarction location  
 Anterior 18(48.64%)
 Inferior 16(43.24%)
 Lateral 3 (8.10%)
*IHD: ischemic heart disease; HLP: hyperlipidemia.
HTN: hypertension; DM: diabetes mellitus; CK: creatine kinase.
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The capacities of the possible variables in the prediction 
of recovery of myocardial function, resulting from a 
change in LVEF, were evaluated using stepwise multiple 
regression analysis after affirmation of non-violation of 
the assumptions of normality, linearity, multicolinear-
ity, and homoscedasticity. Moreover, a p-value <0.05 
was considered significant. Statistical analysis was per-
formed with an IBM computer using the PASW 18.0 
software (SPSS, Inc., Chicago, USA).
Results
Thirty-seven patients (30 men and 7 women; mean age: 
58±14 years) with AMI were enrolled in the study. None 
of them had a history of previous MI. All patients were 
admitted within 6 h after the onset of symptoms (3.45 ± 
1.38 h).The diagnosis of MI was based on the presence 
of at least two of the following criteria: a typical history 
of prolonged chest pain (more than 30 min), transiently 
high serum enzyme levels, and electrocardiographic 
(ECG) signs of MI. According to the ECG, the number of 
cases with anterior, inferior, and lateral MI were 18, 16, 
and 3, respectively (Table 1).
Redistribution
Redistribution was observed in 15 patients in the initial 
scan and 16 patients in the follow-up scan. Overall, redis-
tribution was observed in 69 segments of the LV myocar-
dium, either in the initial scan (mean uptake percent; 
50±13% vs. 55±14) or in the follow-up scan (mean 
uptake percent; 55±12% vs. 61±11%).
Redistribution in the initial scan
Redistribution was observed in 38 segments, totally, 
(49±10 vs. 56±10%); 17 of them exhibited improved 
uptake and redistribution that had disappeared on the 
follow-up scan (62±13% vs. 62±11%) as compared to the 
initial scan (52±12% vs. 60±11%). Nineteen segments 
still had redistribution on the follow-up scan, but with 
improved segmental uptake (initial scan [46±9% vs. 
53±9%] vs. follow-up scan [51±7% vs. 58±68]). Two seg-
ments with redistribution in the initial scan (44±12% vs. 
50±8%) switched to reverse redistribution in the follow-
up scan (50±9% vs. 44±12%).
Redistribution in the follow-up scan
Fifty segments showed redistribution on the follow-up 
scan (52±10 vs. 60±11%). As mentioned previously, 19 
segments with redistribution in the initial scan still had 
redistribution in the follow-up scan. Eight segments 
with normal uptake both in the 30 min and 180 min 
images on the initial scan (64±11 vs. 64±13%) shifted 
to redistribution on the follow-up scan (61±10% vs. 
72±10%). Eleven segments that had reverse redistribu-
tion in the initial scan (58±15% vs. 50±14%) turned to 
redistribution with improved segmental uptake in the 
follow-up scan (55±13% vs. 63±12%). Twelve segments 
with severe perfusion defects on the initial scan (37±9 vs. 
36±10%) also had redistribution on the follow-up scan, 
with some improved uptake in both image sets (46±10 
vs. 55±9%).
In the groups with redistribution on the initial scan, 
a significant difference in the percentage uptake was 
noted between the 30-min and 180-min images on both 
the initial and follow-up scans (p<0.001) (Figure 2). 
Comparing the data of the initial scan with the follow-up 
scan in this group, we detected a significant difference in 
the percentage uptake of the 30-min images (p<0.001), 
whereas there was no such difference in the 180-min 
images.
On the other hand, in patients who showed the pres-
ence of redistribution in both the initial and follow-up 
scans, there were statistically considerable differences in 
percentage uptake between the 30-min and 180-min 
image sets on the initial (p<0.001) as well as the follow-
up scan images (p<0.05). Comparing the data of the ini-
tial scan with those of the follow-up scan in this group, 
we detected significant differences in the percentage 
uptake of both 30-min and 180-min images (p<0.001) 
(Figures 3, 4).
In the comparison of total wall motion abnormality 
scores in patients with redistribution in both the initial 
and follow-up scans, a significant difference between ini-
tial and follow-up echocardiograph scoring was noted 
(p<0.001) (Tables 2, 3).
Reverse redistribution
Reverse redistribution in the initial scan. From 37 patients, 
25 (67%) had reverse redistribution in the initial scan; of 
these, 20 cases showed an improved uptake in the follow-up 
scan in both the 30-min and 180-min images. In the 20 
cases with improvement uptake, 13 patients (65%) 
presented an improvement of segmental wall motion and 
more than 5% augmentation of LVEF, defined as viable 
myocardium.
Reverse redistribution in the follow-up scan. From a total of 
25 patients with initial reverse redistribution, 21 also 
showed reverse redistribution in the follow-up scan; of 
these, 10 cases exhibited improvement in the LVEF and 
wall motion abnormality. No new case of reverse redistri-
bution was observed in the follow-up scan (Figure 5).
There was a significant difference in both LVEF and 
wall motion abnormality between the initial and follow-
up echocardiography (p<0.001).
Comparison of total perfusion defects in patients 
with and without reverse redistribution revealed a 
noticeable difference in the 180-min images, both in the 
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initial and the follow-up scans; however, such a relation-
ship was observed in the 30-min images only in the fol-
low-up scan (p<0.05).
Segmental study of reverse redistribution in the initial 
and the follow-up scintigraphy are depicted in Figure 3.
Six segments of all 52 segments that exhibited perfu-
sion defect, with a score ≤2 on the initial scan, showed 
better uptake on the 180-min images compared to the 
30-min images (redistribution). Furthermore, all of these 
segments showed complete improvement in the regional 
wall motion abnormality and an increment of LVEF ≥ 5%.
There was a significant difference in the total per-
fusion defect score between the 30-min and 180-min 
images on the initial scan (p<0.001) and the 30-min and 
Figure 2. Images of a 55-year-old patient who received thrombolytic therapy.
In the initial scan (Figure 2A), a mild perfusion defect in the inferior wall that is more striking on the 180-min images is seen. In the follow-up scan 
(Figure 2B), some improvement in uptake is seen on the 30- and 180-min images; however, some perfusion defects are still visible, which are more 
prominent on the 180-min images. In the first echocardiograph, severe hypokinesia was seen in the inferior and inferobasal walls; in the follow-up 
echocardiograph, mild hypokinesia in the inferobasal walls was noted.
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180-min images on the follow-up scan (p<0.001). In the 
patients with reverse redistribution, a significant differ-
ence was seen in the total perfusion defect score on the 
initial and follow-up scans (p<0.001, p<0.001) and the 
total wall motion abnormality score on the initial and 
follow-up echocardiograms (p<0.001, p<0.001) (Tables 
2, 3). In the patients who still had reverse redistribution 
in the follow-up scan, there was no significant difference 
between 30-min images in total perfusion score, but 
there was a significant difference in the 180-min images 
(p=0.066 vs. p=0.004) (Figures 6, 7).
Association of clinical and scintigraphic 
parameters with ejection fraction changes
The patients were classified into three groups in accor-
dance with wall motion and LVEF improvement. 
Complete improvement of regional wall motion abnor-
mality and the increase of LVEF in the follow-up of 
echocardiography were seen in 9 cases (Group 1). 
Fourteen cases had an increment of LVEF of more than 
5%, but still had some of the regional wall motion abnor-
mality (Group 2). The 14 remaining patients showed no 
significant changes in the LVEF (<5%) or improvement 
in regional wall motion abnormality (Group 3).
There was no significant difference among the main 
risk factors such as age, sex, hypertension, diabetes mel-
litus, hyperlipidemia, and history of ischemic heart dis-
ease (IHD) in the three groups (p>0.05). The number of 
vessel involvements in the 3 groups was not significantly 
statistically different (p>0.05). These groups were well 
matched with respect to concomitant therapy with other 
drugs such as aspirin, beta-blockers, and inhibitors of the 
rennin-angiotensin system. The majority of the patients 
received all these treatments.
There was a significant difference in the infarcted 
myocardial regions (p<0.001), time of onset of symp-
toms to treatment with fibrinolysis (p<0.001), and level 
of creatine kinase (p<0.001). The presence of reverse 
redistribution in the first and second sets and redistribu-
tion in the second set were statistically significant in the 
three groups (p<0.05), while redistribution in the first 
set showed no significant difference (p=0.26). The other 
basic data are shown in table 4.
Multivariate linear analyses adjusting for main clini-
cal risk factors revealed that CMR1, CMR2, CMR3, 
Figure 3. Segmental uptake percentage of 4 images in patients with normal, redistribution, reverse redistribution, and severe defect 
patterns on the initial scan.
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LHR4, and age were the independent determinants for 
prediction of ejection fraction change across different 
models in the patients (Table 5).
Prediction of improvement in regional 
ventricular function
To determine the prediction of perfusion uptake level for 
the final outcome of each segment, ROC curve analysis 
was performed separately for 4 image sets. The area 
under the ROC curve was 0.725±0.05 (p<0.001) for 
the 30-min initial scan, 0.719±0.043 (p<0.000) for the 
180-min initial scan, 0.783±0.053 (p<0.001) for the 
30-min follow-up scan, and 0.754±0.05 (p<0.060) for the 
180-min follow-up scan. Furthermore, using the optimal 
cut-off point of perfusion percentage in each image set, 
sensitivity as well as specificity and the likelihood ratio 
Figure 4. Segmental uptake percentage of 4 images in patients with normal, redistribution, and reverse redistribution patterns on 
the follow-up scan.
Table 2. Main scintigraphic findings
1st image 2nd image 3rd image 4th image
SPS 12.54±14.95 12.86±15.08 8.13±11.29 8.54±11.06
LHR 0.41±0.07 0.35±0.05 0.39±0.07 0.34±0.06
Percentage uptake territory  
LAD 60.54 ± 16.61 58.62±16.75 65.04±13.58 63.56±15.47
RCA 57.80±9.31 56.68±8.88 59.30±9.94 59.21±8.73
LCX 71.94±11.02 71.37±9.29 72.56±10.91 70.95±10.22
SPS: sum perfusion score; LHR: lung heart ratio; LAD: left anterior descending artery.
RCA: right coronary artery, LCX: left circumflex artery.
Table 3. Echocardiography findings
1st time 2nd time
Echo. Score 16.54±14.55 10.97±13.86
LVDD (%) 48.47±5.72 46.85±9.75
EF(%) 46.00±8.79 50.97±10.39
LVDD: left ventricular end-diastolic cavity dimension; EF: ejection fraction.
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Figure 5. Segmental study of reverse redistribution in initial and follow-up scintigraphy.
Figure 6. Comparison of sum perfusion score of 4 images in patients who had reverse reperfusion on the initial scan.
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Figure 7. Comparison of sum perfusion score of 4 images in patients who had reverse reperfusion on the follow-up scan.
Table 4. The basic scintigraphy and echocardiography data of 3 groups
variable Group 1 Group 2 Group 3 P value
SPS1 3.89±11.66 25.79±13.46 4.86±7.03 0.000
SPS2 0.00±0.00 19.36±11.23 2.14±2.65 0.000
SPS3 3.44±10.33 26.21±14.03 5.57±7.55 0.000
SPS4 0.00±0.00 20.50±10.54 2.07±3.79 0.000
LHR1 0.38±0.09 0.43±0.06 0.42±0.07 0.240*
LHR2 0.32±0.06 0.38±0.06 0.35±0.04 0.063*
LHR3 0.33±0.05 0.42 ±0.08 0.39±0.05 0.015
LHR4 0.29±0.03 0.37±0.07 0.34±0.04 0.020
LVDD1 44.33±2.90 50.92±7.56 48.70±3.16 0.021
LVDD2 42.35±3.73 48.63±14.85 47.97±3.88 0.284*
EF2 58.89±2.14 40.86±9.02 56.00±5.84 0.000
EF1 51.78±2.53 38.07±7.68 50.21±6.41 0.000
Echo. Score 1 3.89±1.83 30.93±13.04 10.29±6.19 0.000
Echo. Score 2 0.22±0.44 24.86±13.33 4.00±3.84 0.000
SPS1,2,3,4: sum perfusion score in first ,second, third and fourth image, respectively; LHR1,2,3,4: lung heart ratio in first ,second, third and fourth 
image, respectively; LVDD1,2: left ventricular end-diastolic cavity dimension in first and second time, respectively; EF1,2: ejection fraction in first and 
second time, respectively.
*All variables except LHR1, LHR2 and LVDD2 were statistically significant.
418 Perfusion 26(5)
(LR) for the improvement of regional wall motion after 
3–5 months were defined; these are reported in Table 6.
Discussion
Redistribution
This study demonstrates that rest redistribution after 
thrombolytic therapy is a marker of viability, along with 
improvement of segmented perfusion uptake and the 
recovery of regional wall motion abnormality. 99mTc-
sestamibi is a lipophilic, cationic complex that is taken up 
by myocardial tissue in proportion to myocardial blood 
flow4,5,23. The initial distribution of 99mTc-sestamibi 
after administration is related to both cellular extraction 
and regional perfusion; the filling in of an initial defect 
over time has been referred to as redistribution, and has 
been attributed to differential washout of the tracer from 
the ischemic and normal myocardium24. However, 
99mTc-sestamibi is not a pure flow tracer, and retention 
of the tracer is also dependent on cellular viability7-9,25. In 
canine models of infarction, when 99mTc-sestamibi is 
administered during reperfusion, the late distribution of 
99mTc-sestamibi primarily reflects viability, not flow8,9. 
Okada et al.5 demonstrated a difference in the clearance 
of 99mTc-sestamibi from ischemic and non-ischemic 
regions in a model of occlusion and reperfusion. Dilsizain 
et al.26 reported that 3- to 4-hour delay rest 99mTc-sesta-
mibi imaging significantly improved the identification of 
reversible thallium-201 defects in comparison to stan-
dard stress-rest 99mTc-sestamibi SPECT images, and 
redistribution was observed in 22% of patients.
Furthermore, this study showed that patients with 
significant myocardial salvage in perfusion scintigraphy 
showed no improvement in regional wall motion by 
echocardiography until several weeks after infarction. 
Conversely, patients without scintigraphic improvement 
following thrombolytic therapy had no improvement in 
their serial echocardiograms. These results stress the 
importance of perfusion scintigraphy for assessing myo-
cardial salvage, because LV stunning within the infarcted 
zone or hyperkinesis in non-infarct regions early post 
infarction can be misleading20.
Reverse redistribution
Reverse redistribution has been most commonly observed 
following coronary thrombolytic and percutaneous trans-
luminal coronary angioplasty (PTCA), which is frequently 
associated with patency of the infarct-related artery and 
fairly preserved infarct segment wall motion13,15,27. It 
has also been described soon after bypass surgery and a 
variety of cardiomyopathies, including Chagas disease and 
Table 5. Multiple linear regression analysis for the correlation 
between ejection fraction change (as dependent variable) with 
clinical and scintigraphic variables (as independent variables) 
across different models of the patient
Variable EF change  
 β ρ R2
Model 1 0.22
 Age 0.40 0.010  
 SPS1 0.002 0.995  
 CMR1 0.36 0.017  
 LHR1 −0.091 0.594  
Model 2 0.26
 Age 0.41 0.007  
 SPS2 −0.11 0.588  
 CMR2 0.45 0.004  
 LHR2 −0.27 0.11  
Model 3 0.27
 Age 0.29 0.048  
 SPS3 −0.03 0.975  
 CMR3 0.45 0.003  
 LHR3 −0.22 0.202  
Model 4 0.23
 Age 0.25 0.086  
 SPS4 −0.11 0.505  
 CMR4 0.23 0.170  
 LHR4 −0.50 0.002  
All models were adjusted for sex, smoking, diabetes mellitus( DM), hy-
pertension (HTN), hyperlipidemia (HLP), location of MI, time from attack 
until hospital admission, number of vessel involvement on angiography, 
hospitalization days, kind of added fibrinolytic to streptokinase (unfrac-
tionated heparin (UFH) vs. enoxaparin) and also history of ischemic 
heart disease (IHD).
SPS: sum perfusion score; LHR: lung heart ratio; CMR: cavity to myocar-
dium count ratio.
Table 6. The statistical parameters in different cut-off values in each image for prediction of improvement in regional ventricular 
function
Image Cut-off (%) Sensitivity (%) Specificity(%) LR
Initial 30 min. 33.50 80 49 1.56
Initial 180 min. 29.50 90 49 1.76
Follow-up 30 min. 35.50 93 52 1.93
Follow-up 180 min. 33.50 91 50 1.82
LR: Likelihood Ratio.
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sarcoidosis28-30. Pace et al.31 reported, in the resting 99mTc-
sestamibi, that segments with reverse redistribution are 
frequently subtended by occluded epicardial vessels (46%), 
often in association with “good collateral” circulation 
(58%) and such segments also have abnormal wall motion 
and decreased 99mTc-sestamibi uptake and concluded 
that segments with reverse redistribution clinically resem-
ble fixed defect; on the other hand, Weiss et al.13 found 
reverse redistribution to be associated with patent arteries. 
Our results indicate that 99mTc-sestamibi can enter 
injured, but viable cells after thrombolytic therapy, but is 
released over the course of several hours due to sarcolem-
mal and/or mitochondrial dysfunction caused by isch-
emia; therefore, a myocardium with reverse redis tribution 
seems viable. When this sarcolemmal and/or mitochon-
drial dysfunction recovers, the reverse redi stribution of 
99mTc-sestamibi in AMI disappears. Therefore, patients 
with reverse redistribution will show improvement of 
regional wall motion abnormalities and segments with 
reverse redistribution that has disappeared exhibit greater 
improvement in the wall motion of the myocardium.
Association of clinical and scintigraphic 
parameters with ejection fraction changes
Fibrinolytic therapy, such as the administration of strep-
tokinase, is the most common form of reperfusion 
therapy in patients with MI, and is administered for cases 
without contraindications. However, complete early 
reperfusion is accomplished in only about a third of 
patients32, and re-occlusion is experienced in about 10% 
of patients in hospital and in about one-third of patients 
at their 3-month follow-up33.
Determination of the degree of myocardial salvage 
after infarction is very important in the management 
of patients. Quantification of myocardial salvage has 
been attempted by assessing changes in the regional and 
global left ventricular function10 and by myocardial 
perfusion imaging using quantitative planar and tomo-
graphic techniques26. This study showed that age and 
CM ratio in the early days of hospital admission corre-
late well with relative functional improvement and, 
when controlling for other clinical and scintigraphic 
variables, can predict the recovery of myocardial func-
tion after myocardial insult and successful thrombolytic 
therapy. In contrast, we also found that the LHR on the 
follow-up scan could be a good predictor of recovery of 
myocardial function after thrombolytic therapy; this is 
in concordance with previous reports34-36. The calcu lation 
of LHR with various radiotracers like thallium-20137, 
99mTc-sestamibi38, and 99mTc-tetrofosmin39 seems to 
be a significant prognostic value in different situations, 
such as post-thrombolytic therapy, post unstable angina 
and non-Q MI, post coronary artery bypass grafting, 
and in patients with severe post-ischemic left ventricular 
dysfunction34-37.
Prediction of improvement in regional 
ventricular function
This study also showed that a 35% threshold of 99mTc-
sestamibi activity had a sensitivity greater than 90%, 
specificity greater than 50%, and an LR greater than 1.5.
Dakik et al. showed that a 55% threshold of 99mTc-
sestamibi activity had positive and negative predictive 
values of 79% and 100%, respectively40. In another study, 
the authors demonstrated that using an infarct location-
adjusted optimal threshold (50% for anterior infarcts, 
35% for inferior infarcts), 99mTc-sestamibi had a posi-
tive predictive value of 90% and a negative predictive 
value of 91% for the improvement of left ventricular 
function41. The reasons for this discrepancy lie in diverse 
cut-off values and differences in the study population, 
acquisition protocol, reference of recovery (echocardiog-
raphy vs. angiography), time of post-MI scanning, con-
sideration of rest scanning without stress or nitrate 
administration, and, most importantly, exclusion of 
cases with intervention (CABG or percutaneous coro-
nary intervention[ PCI]) in our study.
Several other studies have also claimed that quantita-
tive regional 99mTc-sestamibi activity increases the 
accuracy of detecting viable myocardium, as evidenced 
by preserved metabolic activity26, histological evaluation 
of myocardial fibrosis42, or improvement in ventricular 
function after revascularization43. However, it is difficult 
to define a lower limit of 99mTc-sestamibi activity that 
reliably excludes viability.
Finally, these findings support the claim that adding 
quantitative myocardial perfusion imaging to routine 
diagnostic modalities in patients with STEMI could be 
useful, although further evidence needs to be found.
Limitations of the study
One of the most important limitations is the relatively 
small sample size; however, it was quite homogenous 
in terms of cardiovascular risk factors. For acquiring 
myocardial perfusion SPECT, we used a low-energy, all-
purpose collimator, whereas a high resolution collimator 
could have resulted in more precise detection of redis-
tributed segments; comparison with thallium-201 perfu-
sion SPECT should also be considered. However, the 
patient’s dose exposure is the milestone in such parallel 
comparisons. In addition, we could not perform gated 
SPECT imaging because of the high frequency of cardiac 
arrhythmia. The other major limitation of the study is 
that motion occurred during the echocardiography, 
which uses an operator-dependent instrument. Also, we 
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did not apply attenuation correction (AC) during image 
processing; the data regarding the inferior wall might be 
hampered by this shortcoming. Furthermore, some seg-
ments may have more improvement in the recovery wall 
motion or percentage perfusion uptake in a prolonged 
time course; extended monitoring is among the param-
eters that should be taken into account in future studies.
Conclusion
This study demonstrated that the redistribution and 
reverse redistribution of 99mTc-sestamibi in patients 
with AMI who received thrombolytic therapy and 
regional wall motion abnormalities (stunning) improved 
in the follow-up monitoring, indicating a viable myo-
cardium. The study also demonstrated that resting 
99mTc-sestamibi SPECT perfusion can be used for an 
approximate assessment of LV function status and can 
predict the recovery of jeopardized myocardium func-
tion after thrombolytic therapy. However, further well-
designed studies to assess these results that follow 
patients for a longer period of time are needed.
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